HFA beclomethasone dipropionate (HFA-BDP) extrafine aerosol and formoterol in optimizing the management of bronchial asthma at children

N. A. Geppe, N. G. Kolosova, M. N. Snegotskaya (Moscow, Russian Federation)

Source: Annual Congress 2005 - Paediatric asthma drug therapy
Session: Paediatric asthma drug therapy
Session type: Thematic Poster Session
Number: 1045
Disease area: Airway diseases, Paediatric lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. A. Geppe, N. G. Kolosova, M. N. Snegotskaya (Moscow, Russian Federation). HFA beclomethasone dipropionate (HFA-BDP) extrafine aerosol and formoterol in optimizing the management of bronchial asthma at children. Eur Respir J 2005; 26: Suppl. 49, 1045

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Comparison of a new extrafine beclomethasone dipropionate HFA134a-formulated pMDI with a standard BDP CFC pMDI in adults with moderate persistent asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 206s
Year: 2006

A pharmaco-epidemiological audit of beclomethasone dipropionate extrafine aerosol in patients with asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 471s
Year: 2002

Effects of the changing from chlorofluorocarbon (CFC)- beclomethasone dipropionate (BDP) to hydrofluoroalkane (HFA)-BDP on pulmonary function in asthmatic children
Source: Annual Congress 2007 - Anti-inflammatory therapy for childhood asthma
Year: 2007


Long-term benefits of switching to hydrofluoroalkane beclomethasone dipropionate extrafine aerosol
Source: Eur Respir J 2001; 18: Suppl. 33, 331s
Year: 2001

QVAR pMDI is more cost effective than CFC-beclometasone dipropionate (BDP) pMDI in a real-life asthmatic population initiating ICS
Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care
Year: 2009

Use of hydrofluoroalkane beclomethasone dipropionate (HFA-BDP) extrafine aerosol in optimising the management of allergic bronchopulmonary aspergillosis (ABPA)
Source: Eur Respir J 2003; 22: Suppl. 45, 237s
Year: 2003

Salmeterol and beclomethasone dipropionate versus higher dose beclomethasone dipropionate in asthma patients
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005

Acceptability and efficacy of beclomethasone dipropionate (Béclojet HFA®) and fluticasone dipropionate (Flixotide HFA®, FDP) associated with the Volumatic® spacer in adults with mild to moderate persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 473s
Year: 2003

HFA vs CFC beclomethasone dipropionate – comparative effectiveness in asthma management
Source: Eur Respir J 2006; 28: Suppl. 50, 498s
Year: 2006

Comparison of a new HFA 134a-formulated budesonide pMDI with a standard CFC-formulated budesonide pMDI in children with persistent asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 160s
Year: 2005

Therapeutic equivalence of beclomethasone dipropionate/formoterol administered via NEXTTM DPI with beclomethasone dipropionate/formoterol administered via HFA pMDI in adult asthmatic patients
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010

QVAR pMDI is more cost-effective than fluticasone propionate (FP) or CFC-beclometasone dipropionate (BDP) PMDI in a real-life asthmatic population receiving an increase in ICS dose
Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care
Year: 2009

Nebulized beclomethasone dipropionate is as effective and as well tolerated than nebulized budesonide to prevent asthma exacerbations in infants
Source: Eur Respir J 2001; 18: Suppl. 33, 122s
Year: 2001

Efficacy and safety of the new beclomethasone dipropionate/formoterol combination vs. fluticasone propionate/salmeterol pMDIs in moderate to severe persistent asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006

Reduction in air trapping and dyspnea with an extrafine combination of beclomethasone and formoterol in COPD
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

Clinical efficacy of seretide and beclomethasone dipropionate in patients with corticosteroid-dependent bronchial asthma and quality of life
Source: Eur Respir J 2004; 24: Suppl. 48, 285s
Year: 2004

Inhalation of beclomethason dipropionate spray compared with theophilline as primary treatment for chronic mild-to-moderate asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 42s
Year: 2002

Comparative clinical study of addition theophylline to low-dose inhaled beclomethasone dipropionate and medium-dose inhaled beclomethasone dipropionate in patients with mild-to-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 98s
Year: 2001

The clinical effectiveness of HFA-beclomethasone dipropionate in children with moderate asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 166s
Year: 2004

Lung deposition of the extrafine dry powder fixed combination beclomethasone dipropionate plus formoterol fumarate via the NEXT DPI® in healthy subjects, asthmatic and COPD patients
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011